FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2404691305> ?p ?o ?g. }

• W2404691305 abstract "Background: Sentinel lymph node biopsy (SLNB) is the current standard of care for surgical staging of clinically node negative axilla (N0) early breast cancer patients undergoing primary surgery. SLN- identification rate (IR) of 90% and SLN- false negative rate (FNR) of 10% are considered minimum acceptable indices for SLNB. Its role in staging axillae in patients undergoing post-NACT surgery is somewhat unclear. In India, and most low-and-middle income countries, large operable breast cancers (LOBC) and locally advanced breast cancers (LABC) constitute a large proportion of breast cancer patients treated. These patients are usually are treated with NACT, followed by surgery and radiation therapy. In a prospective validation SLNB study, we investigated the accuracy of SLNB in staging post-NACT N0 axilla in a patient cohort that were LOBC or LABC at the time of initial presentation. Methods: Hundred consenting non-inflammatory LOBC/LABC patients (mean age 49.3+8.6; index stage T3,N0-1=21; T4b,N0-1=33; T1-3,N2a=24; T4b,N2a=22) who were N0 after NACT at time of surgery (Breast conservation surgery in 19, Mastectomy in 81) were included. Majority had Infiltrating ductal carcinoma (n=87), and grade II/III tumors (n=93); 45 were hormone receptor positive (+), 29 had HR negative (-) HER2(+); and 26 had triple negative breast cancer on IHC sub-typing. Commonest NACT regimen used was Anthracycline followed by taxanes in 83. SLNB was performed using low-cost methylene-blue and 99mTc-Antimony-colloid, which were produced in-house using well standardized protocols, with clearance of the institutional ethics committee. Irrespective of the SLN histology, a complete axillary dissection (ALND) was carried out in all. SLN-IR and SLN-FNR were calculated, comparing the histological status of the SLN and the ALND specimen. Factors predicting non-identified SLN and false negative SLN were evaluated in uni-variate and multi-variate analysis. Results: With a combination of methylene blue dye and radiopharmaceutical, the SLN-IR was 81%. Mean number of SLN removed was 2.4+/-1.02. Mean number of nodes removed at ALND was 13.3+/-2.2. SLN-IR varied significantly (p Conclusions: Considering SLN-IR of 90% and SLN-FNR of 10% as acceptable standards, SLNB in post-NACT N0 patients undergoing surgery was not found robust in staging the axilla, with the exception of patients with index stage T3,N0-1 who had SLN-IR of 90.4% and SLN-FNR of 8.3%. Patients with (pre-NACT) skin involvement(T4b), matted axillary nodes(N2a) and LVI are fraught with high-risk of non-identification and false-negative SLNB. Citation Format: Agarwal G, Gambhir S, Lal P, Rajan S, Krishnani N, Mishra A, SabaRetnam M, Agarwal A, Chand G, Verma AK, Mishra SK, Kumari N, Agrawal V, Kheruka SC. Sentinel lymph node biopsy after NACT: Results of a validation study in large/locally advanced breast cancer patients. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P3-01-06." @default.
• W2404691305 created "2016-06-24" @default.
• W2404691305 creator A5001124451 @default.
• W2404691305 creator A5004845240 @default.
• W2404691305 creator A5015458122 @default.
• W2404691305 creator A5020341898 @default.
• W2404691305 creator A5038362111 @default.
• W2404691305 creator A5042672044 @default.
• W2404691305 creator A5044424305 @default.
• W2404691305 creator A5056992469 @default.
• W2404691305 creator A5066104512 @default.
• W2404691305 creator A5067428033 @default.
• W2404691305 creator A5070153059 @default.
• W2404691305 creator A5070945589 @default.
• W2404691305 creator A5083863332 @default.
• W2404691305 creator A5088720600 @default.
• W2404691305 date "2016-02-15" @default.
• W2404691305 modified "2023-09-27" @default.
• W2404691305 title "Abstract P3-01-06: Sentinel lymph node biopsy after NACT: Results of a validation study in large/locally advanced breast cancer patients" @default.
• W2404691305 doi "https://doi.org/10.1158/1538-7445.sabcs15-p3-01-06" @default.
• W2404691305 hasPublicationYear "2016" @default.
• W2404691305 type Work @default.
• W2404691305 sameAs 2404691305 @default.
• W2404691305 citedByCount "0" @default.
• W2404691305 crossrefType "proceedings-article" @default.
• W2404691305 hasAuthorship W2404691305A5001124451 @default.
• W2404691305 hasAuthorship W2404691305A5004845240 @default.
• W2404691305 hasAuthorship W2404691305A5015458122 @default.
• W2404691305 hasAuthorship W2404691305A5020341898 @default.
• W2404691305 hasAuthorship W2404691305A5038362111 @default.
• W2404691305 hasAuthorship W2404691305A5042672044 @default.
• W2404691305 hasAuthorship W2404691305A5044424305 @default.
• W2404691305 hasAuthorship W2404691305A5056992469 @default.
• W2404691305 hasAuthorship W2404691305A5066104512 @default.
• W2404691305 hasAuthorship W2404691305A5067428033 @default.
• W2404691305 hasAuthorship W2404691305A5070153059 @default.
• W2404691305 hasAuthorship W2404691305A5070945589 @default.
• W2404691305 hasAuthorship W2404691305A5083863332 @default.
• W2404691305 hasAuthorship W2404691305A5088720600 @default.
• W2404691305 hasConcept C121608353 @default.
• W2404691305 hasConcept C126322002 @default.
• W2404691305 hasConcept C126838900 @default.
• W2404691305 hasConcept C141071460 @default.
• W2404691305 hasConcept C143998085 @default.
• W2404691305 hasConcept C146357865 @default.
• W2404691305 hasConcept C151730666 @default.
• W2404691305 hasConcept C2775934546 @default.
• W2404691305 hasConcept C2776608951 @default.
• W2404691305 hasConcept C2777757722 @default.
• W2404691305 hasConcept C2780212769 @default.
• W2404691305 hasConcept C530470458 @default.
• W2404691305 hasConcept C71924100 @default.
• W2404691305 hasConcept C86803240 @default.
• W2404691305 hasConceptScore W2404691305C121608353 @default.
• W2404691305 hasConceptScore W2404691305C126322002 @default.
• W2404691305 hasConceptScore W2404691305C126838900 @default.
• W2404691305 hasConceptScore W2404691305C141071460 @default.
• W2404691305 hasConceptScore W2404691305C143998085 @default.
• W2404691305 hasConceptScore W2404691305C146357865 @default.
• W2404691305 hasConceptScore W2404691305C151730666 @default.
• W2404691305 hasConceptScore W2404691305C2775934546 @default.
• W2404691305 hasConceptScore W2404691305C2776608951 @default.
• W2404691305 hasConceptScore W2404691305C2777757722 @default.
• W2404691305 hasConceptScore W2404691305C2780212769 @default.
• W2404691305 hasConceptScore W2404691305C530470458 @default.
• W2404691305 hasConceptScore W2404691305C71924100 @default.
• W2404691305 hasConceptScore W2404691305C86803240 @default.
• W2404691305 hasLocation W24046913051 @default.
• W2404691305 hasOpenAccess W2404691305 @default.
• W2404691305 hasPrimaryLocation W24046913051 @default.
• W2404691305 hasRelatedWork W12909323 @default.
• W2404691305 hasRelatedWork W13181339 @default.
• W2404691305 hasRelatedWork W13334268 @default.
• W2404691305 hasRelatedWork W14561912 @default.
• W2404691305 hasRelatedWork W20048081 @default.
• W2404691305 hasRelatedWork W364012 @default.
• W2404691305 hasRelatedWork W3890940 @default.
• W2404691305 hasRelatedWork W8076426 @default.
• W2404691305 hasRelatedWork W9156384 @default.
• W2404691305 hasRelatedWork W17213086 @default.
• W2404691305 isParatext "false" @default.
• W2404691305 isRetracted "false" @default.
• W2404691305 magId "2404691305" @default.
• W2404691305 workType "article" @default.